-
West Indies 'tick boxes' in shortened T20 against South Africa
-
Chelsea have something 'special' says Rosenior
-
De Zerbi 'ready to go to war' to solve Marseille troubles
-
Hornets hold off Wemby's Spurs for sixth NBA win in a row
-
Moyes blasts killjoy booking after Everton's late leveller
-
Ex-prince Andrew again caught up in Epstein scandal
-
Bayern held at Hamburg to open door for Dortmund
-
Atletico stumble to draw at Levante, Villarreal held
-
Chelsea stage impressive fightback to beat West Ham
-
Arsenal stretch Premier League lead, Chelsea fightback breaks Hammers' hearts
-
Napoli edge Fiorentina as injury crisis deepens
-
How Lego got swept up in US-Mexico trade frictions
-
UK rights campaigner Tatchell arrested at pro-Palestinian protest
-
Iran says progress made towards US talks despite attack jitters
-
'Empowering': Ireland's first female sumo wrestler blazes a trail
-
US judge denies Minnesota bid to suspend immigration sweeps
-
Ukraine hit by mass power outages after 'technical malfunction'
-
AC Milan prolong France 'keeper Maignan deal by five years
-
Arteta hails Arsenal's statement rout of Leeds
-
Marseille buckle as Paris FC battle back for draw
-
Protesters demand 'justice' one month after Swiss bar fire
-
Philadelphia's Paul George gets 25-game NBA drugs ban
-
La Rochelle suffer defeat after shock Atonio retirement
-
'It wasn't working': Canada province ends drug decriminalization
-
Kishan, Arshdeep star as India down New Zealand in T20 finale
-
Moreno bags brace but Villarreal held at Osasuna
-
Kramaric keeps in-form Hoffenheim rolling in Bundesliga
-
'Skimo': Adrenalin-packed sprint to make Olympic debut
-
Venezuela's 'Helicoide' prison synonymous with torture of dissenters
-
Arsenal thrash Leeds to stretch Premier League advantage
-
Russia's Valieva returns to ice after doping ban
-
Snow storm barrels into southern US as blast of icy weather widens
-
Ukraine sees mass power outages from 'technical malfunction'
-
Gaza civil defence says Israeli strikes kill 32
-
Kirsty Coventry set to give clues to her Olympic vision in Milan
-
I'm no angel, Italy's PM says amid church fresco row
-
Thousands join Danish war vets' silent march after Trump 'insult'
-
Gaza civil defence says Israeli strikes kill 28
-
Pakistan spin out Australia in second T20I to take series
-
Melbourne champion Rybakina never doubted return to Wimbledon form
-
Luis Enrique welcomes Ligue 1 challenge from Lens
-
Long truck lines at Colombia-Ecuador border as tariffs loom
-
Ex-prince Andrew dogged again by Epstein scandal
-
Separatist attacks in Pakistan kill 21, dozens of militants dead
-
'Malfunction' cuts power in Ukraine. Here's what we know
-
Arbeloa backs five Real Madrid stars he 'always' wants playing
-
Sabalenka 'really upset' at blowing chances in Melbourne final loss
-
Britain, Japan agree to deepen defence and security cooperation
-
Rybakina keeps her cool to beat Sabalenka in tense Melbourne final
-
France tightens infant formula rules after toxin scare
US tells pharmas to make Covid boosters targeting BA.4 and BA.5
The US Food and Drug Administration on Thursday told vaccine makers that Covid boosters for this fall and winter should include components targeting the BA.4 and BA.5 sublineages of Omicron.
Earlier this week, a panel of medical experts convened by the agency voted in favor of updating Covid vaccines against Omicron, with most indicating they would favor shots that target the latest iterations rather than its original form, BA.1, fearing the latter would be too out-of-date.
BA.4 and BA.5, which are more transmissible and immune evasive, now comprise more than 52 percent of US Covid cases, according to an official tracker.
"We have advised manufacturers seeking to update their Covid-19 vaccines that they should develop modified vaccines that add an omicron BA.4/5 spike protein component to the current vaccine composition to create a two component (bivalent) booster vaccine," the FDA said in a statement.
These vaccines would also need to target the original Wuhan strain, in order to increase the breadth of immune response.
Pfizer and Moderna, which produce messenger RNA Covid vaccines, have developed and tested vaccines against BA.1, and representatives of both companies indicated during the experts' meeting they would need around three months to produce BA.4 and BA.5 vaccines at scale.
Pfizer shared early results showing its BA.4/5 vaccine produced a strong antibody response in mice, but it hasn't yet been trialed in humans.
Novavax, which makes a protein subunit vaccine, said it could offer BA.4/5 vaccines by the end of the year.
The FDA said in its new statement that the companies would need to submit human data prior to authorization.
The "primary series" or first shots a person receives would remain against the original strain, the FDA added.
While previous "variants of concern" like Alpha and Delta eventually petered out, Omicron and its sublineages have dominated throughout 2022, to the point it comprises the vast majority of all Covid in the world, FDA official Jerry Weir told the expert meeting this week.
This makes it more likely that the virus's future evolution will also occur along the Omicron branch of the Covid family tree, he added.
Earlier this month, the World Health Organization also recommended the use of Omicron boosters after a primary series against the original strain.
N.Walker--AT